XML 65 R55.htm IDEA: XBRL DOCUMENT
v3.23.1

Geneos Therapeutics, Inc. - Narrative (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 01, 2020 | Mar. 31, 2022 | Nov. 30, 2020 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2019 | Dec. 31, 2022 | Feb. 28, 2021 | Jun. 30, 2020 | Jan. 31, 2020
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire additional interest in subsidiaries |  |  |  | $ 0 | $ 1,999,998 |  |  |  |  |  |
Share of net loss in Geneos |  |  |  | $ 0 | 2,165,213 |  |  |  |  |  |
Geneos Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  | 47.00% |
Series A-2 One Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Remeasurement of Geneos Series A-1 preferred stock |  | $ 165,215 |  |  |  |  |  |  |  |  |
Share of net loss in Geneos |  | 2,165,213 |  |  |  |  |  |  |  |  |
Investment in equity method investments |  | $ 0 |  |  | $ 0 |  |  | $ 1,999,998 |  |  |
Geneos Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Noncontrolling interest, ownership percentage by parent |  | 28.00% | 36.00% | 26.00% | 28.00% |  | 61.00% |  | 35.00% |  | 52.00%
Geneos Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire additional interest in subsidiaries |  |  | $ 1,400,000 |  |  |  | $ 1,200,000 |  |  |  |
Stock purchase agreement, commitment of additional investment |  |  |  |  |  |  |  |  |  | $ 800,000 | $ 800,000
Gain on deconsolidation of investment | $ 4,100,000 |  |  |  |  |  |  |  |  |  |
Remeasurement of Geneos Series A-1 preferred stock | $ 2,400,000 |  |  |  |  |  |  |  |  |  |
Loss from equity method investment, recorded and allocated to investment |  |  |  |  |  | $ 1,500,000 |  |  |  |  |
Share of net loss in Geneos |  |  |  |  |  | 434,000 |  |  |  |  |
Investment in equity method investments |  |  |  |  |  | 0 |  |  |  |  |
Geneos Therapeutics, Inc. | Series A One Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Share of net loss in Geneos |  |  |  |  |  | 819,000 |  |  |  |  |
Geneos Therapeutics, Inc. | Common stock |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Investment in equity method investments |  |  |  |  |  | 0 |  |  |  |  |
Geneos Therapeutics, Inc. | Preferred stock |  |  |  |  |  |  |  |  |  |  |
Noncontrolling Interest [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire additional interest in subsidiaries |  | $ 2,000,000 |  |  |  |  |  |  |  |  |
Share of net loss in Geneos |  |  |  |  |  | 4,200,000 |  |  |  |  |
Investment in equity method investments |  |  |  |  |  | $ 0 |  |  |  |  |

X
- Definition Income (Loss) From Equity Method Investments, Realized And Allocated to Investment + References No definition available. + Details
Name: | ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock Purchase Agreement, Commitment Of Additional Investment + References No definition available. + Details
Name: | ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_DeconsolidationGainOrLossAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_MinorityInterestLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of noncontrolling interest during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |